AcuCort EBIT par action

Que fait AcuCort ? AcuCort AB is a pharmaceutical company based in Lund, Sweden, operating within the Health Care sector. The company focuses on the development, marketing, and sale of oral dissolvable films, specifically targeting medical applications. Its primary product, ISICORT, utilizes dexamethasone, a glucocorticoid, for treating acute allergic reactions and managing nausea and vomiting associated with chemotherapy. AcuCort AB has a small operational footprint, employing four full-time staff members. The company completed its initial public offering (IPO) on April 24, 2017, and is listed under the ticker ACUC.SL with ISIN SE0009695927. It maintains a website at https://acucort.se/ for further information. AcuCort AB operates predominantly in the Nordic region, with its headquarters situated in Lund, Skåne. The company's business model centers on the production and distribution of specialized pharmaceutical products designed to address specific medical needs. While details about its financial performance, market share, or additional product lines are not provided, the company's focus remains on its core product and regional market presence. Its operational scale reflects a startup or early-stage pharmaceutical enterprise with limited resources. The company's website serves as the primary source for updates and corporate information. AcuCort AB's activities are confined to the development and commercialization of oral film technology, emphasizing targeted therapeutic applications in healthcare. AcuCort est l'une des entreprises les plus populaires sur Eulerpool.